Novo Nordisk is expected to announce key readouts from ambitious semaglutide studies testing whether the GLP‑1 agonist can slow Alzheimer’s disease progression. The company has flagged these trials as high‑risk and has publicly acknowledged that definitive evidence for GLP‑1s in neurodegeneration remains unresolved. Despite uncertainty, Novo Nordisk appears to be preparing commercially: recent job postings for Alzheimer’s‑focused marketing and medical affairs roles worldwide suggest planning for potential label expansion. The outcome will be pivotal for semaglutide—which already transformed obesity and diabetes care—and could significantly expand the drug’s indications if positive. Researchers and clinicians caution that mechanistic understanding is incomplete; confirmation in randomized trials and regulatory review will determine whether GLP‑1 therapies become an approved treatment class for Alzheimer’s, with major implications for neurology practice and market dynamics.